How Much Does a Real World Evidence Platform Cost in 2026?

What you are paying for, and what you are renting

An RWE budget has two halves that get confused constantly. The data is rented. Claims, electronic health record extracts, registries and laboratory feeds are licensed under contracts that run per year and often dwarf the software line. The platform is built, and its job is to make the rented data produce evidence a regulator or a payer will accept rather than a slide a reviewer can dismiss. Head of RWE roles that budget only for data end up with expensive assets and analyses that cannot be reproduced six months later when the question comes back.

The build splits into two bands. A first release ingests two or three licensed datasets, maps them to a common data model while retaining the source layer, versions your phenotype and cohort definitions, and records study execution so a result can be regenerated exactly. That is $110,000 to $230,000 across 14 to 20 weeks. The second band adds tokenised linkage across assets, enforcement of contractual use restrictions, extraction from unstructured notes, analysis packaging for submission, and compute cost governance, at $300,000 to $750,000 phased across 9 to 16 months.

Scope band one: ingestion, common data model and reproducibility

• Dataset onboarding: $22,000 to $45,000 per source. Each vendor delivers in its own structure on its own refresh cadence, with its own history restatement behaviour. This line repeats per dataset and is the term that moves your total more than anything else.
• Common data model mapping with source retention: $25,000 to $45,000. Mapping to a shared model while keeping the original values addressable, because the first time a clinician disputes a cohort you will need to show the raw record, not the harmonised one.
• Vocabulary and time grain harmonisation: $20,000 to $38,000. Diagnosis, procedure and drug vocabularies do not align across claims and clinical sources, and a monthly claims grain against an event level clinical grain is a modelling decision with consequences for every subsequent cohort.
• Versioned phenotype and cohort definitions: $26,000 to $48,000. The most valuable line in the build. A cohort definition is your intellectual property, and it belongs in a versioned, reviewable artifact rather than in a script on an analyst's laptop.
• Reproducible execution record: $18,000 to $34,000. Which definition version, against which data version, with which exclusions, producing which counts. This is what turns an analysis into evidence.
• Analyst workspace and development sample: $14,000 to $26,000. A sampled subset analysts iterate against before running the full asset, which is both a productivity and a cost control feature.

Scope band two: linkage, licence enforcement and submission packaging

Tokenised linkage across assets typically runs $45,000 to $110,000 and is priced by how many tokenisation providers and how many assets are in play. It is also the area where getting it subtly wrong produces a cohort that looks plausible and is not. Licence term enforcement is $30,000 to $60,000: encoding which analyses each contract permits, which fields may leave which environment, and which outputs need vendor review before publication. Sponsors treat this as paperwork until a contract renewal negotiation turns on whether they can demonstrate compliance.

Unstructured note extraction runs $60,000 to $180,000 and is the widest line in the category, because the value depends entirely on validating extraction against manual abstraction for your specific endpoints. Analysis packaging for regulatory and payer submission is $35,000 to $75,000. Compute cost governance, covering materialised cohorts, per study cost attribution and query cost estimates surfaced before execution, is $25,000 to $55,000 and pays for itself in the first year on any large claims asset.

What pushes an RWE quote up

• Number and heterogeneity of source datasets. The dominant term. Five vendors is five onboarding projects with five refresh cadences and five restatement behaviours, not one project with five inputs.
• International data. Each country brings its own privacy regime, its own hosting requirement and often its own contractual review of outputs, which turns one environment into several.
• Linkage across assets. Tokenised joins add both engineering and a validation obligation, because a linkage error produces silently wrong cohorts rather than an error message.
• Note extraction with a defensible validation. Extracting an endpoint from clinical text is the cheap part. Proving the extraction agrees with manual abstraction well enough to support a claim is where the budget goes.
• Regulatory rather than internal use. Evidence intended for a submission carries documentation, traceability and reproducibility obligations that internal feasibility work does not.

What brings it down

• Two datasets in release one. Onboard the two assets that answer most of your current questions and prove the model, then add the third and fourth as repeatable onboarding rather than as new architecture.
• Deferring linkage. If your near term questions can be answered within a single asset, defer tokenised linkage. It is expensive, it is validation heavy, and it becomes much easier once your common data model is settled.
• Structured endpoints first. Build the platform on structured claims and clinical data, and add note extraction only for endpoints where the structured data genuinely cannot answer the question.
• Compute governance early rather than late. Materialised cohorts and a development sample cost $25,000 to $55,000 to build and routinely remove more than that from a year of cloud spend on a national claims asset.

A worked example that adds up

A mid size pharma HEOR group licensing a national claims asset and an oncology electronic health record asset, running roughly a dozen evidence questions a year, with two of those intended for payer dossiers. First release:

• Discovery, evidence question review and model selection: $18,000
• Claims asset onboarding: $34,000
• Oncology electronic health record asset onboarding: $38,000
• Common data model mapping with source layer retained: $36,000
• Vocabulary and time grain harmonisation: $28,000
• Versioned phenotype and cohort definitions: $37,000
• Reproducible execution record and analyst workspace: $32,000

That totals $223,000 and ships in about 19 weeks. Phase two adds licence term enforcement at roughly $42,000, compute governance at roughly $38,000, analysis packaging for payer submission at roughly $52,000 and tokenised linkage across the two assets at roughly $75,000. That is $207,000, taking the programme to $430,000. The annual data licences sit entirely outside that number and are, for most groups, the larger figure.

Timeline and what actually paces the work

Development is 14 to 20 weeks for the first release, but the pacing item is usually data delivery, not engineering. A licensed asset arrives on the vendor's schedule, the first delivery is frequently incomplete or restated, and the second refresh is where you discover how the vendor handles history. Sequence the contract so the first full delivery lands before the onboarding sprint rather than during it, and expect two to four weeks of reconciliation on a large claims asset before an analyst should trust a count from it.

Ongoing costs nobody quotes

• Data licences: the dominant recurring line. Sized by your contracts rather than by your software, and they renew whether or not the platform is used well. This is the number that should make you invest in reproducibility, because an analysis you cannot regenerate is an asset you paid for twice.
• Cloud compute: $20,000 to $200,000 a year depending on asset size and analyst behaviour. Without materialised cohorts and a development sample, the same expensive scan runs repeatedly and finance asks why.
• Refresh onboarding. Every time a vendor changes its delivery format or restates history, that is engineering time. Budget it as a standing allowance rather than as an incident.
• Phenotype revalidation. Definitions drift out of date as coding practice changes. Reviewing your core phenotypes annually is a few analyst weeks and it protects every study built on them.
• Maintenance: 15 to 22 percent of build cost per year for the platform itself, higher if outputs feed regulatory submissions.

When you should not build

If you run one feasibility question a quarter, do not build a platform. Use TriNetX for exploration and licence Aetion when a study needs rigour. The cost of a platform is not justified by a handful of questions a year, and a group at that volume has not yet learned enough about its own evidence needs to design the right model.

The build case appears when you license data from several vendors, when the same cohort definition is being rewritten by different analysts, when evidence has to be defensible to a regulator or a payer rather than persuasive internally, or when the compute bill has become a quarterly conversation. In those situations the platform is not buying you analysis capability you lack. It is buying you the ability to answer the second question without rebuilding the first.

If you would rather scope this before committing budget, Digital Heroes builds and runs its own products, so the people choosing your architecture live with those decisions on their own revenue. The document is yours whichever way you go.